Enanta Pharmaceuticals (ENTA)
Market Price (9/19/2026): $12.19 | Market Cap: $354.6 MilSector: Health Care | Industry: Biotechnology
Enanta Pharmaceuticals (ENTA)
Market Price (9/19/2026): $12.19Market Cap: $354.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Weak multi-year price returns2Y Excs Rtn is -38%, 3Y Excs Rtn is -84% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.15 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -59 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -90% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -6.7%, Rev Chg QQuarterly Revenue Change % is -22% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 23% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -54%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -57% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% High stock price volatilityVol 12M is 107% Key risksENTA key risks include [1] the recent clinical trial failure of its lead RSV candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -38%, 3Y Excs Rtn is -84% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.15 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -59 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -90% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -6.7%, Rev Chg QQuarterly Revenue Change % is -22% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 23% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -54%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -57% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% |
| High stock price volatilityVol 12M is 107% |
| Key risksENTA key risks include [1] the recent clinical trial failure of its lead RSV candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Enanta Pharmaceuticals (ENTA) stock has lost about 5% since 5/31/2026 because of the following key factors:
1. Significant Decline in Royalty Revenue.
Enanta Pharmaceuticals' total revenue for fiscal Q3 2026 (which ended June 30, 2026, as the company's fiscal year ends on September 30) sharply decreased by 21.6% year-over-year, to $14.4 million. This substantial reduction was primarily driven by lower royalty revenue from global net sales of AbbVie's hepatitis C virus (HCV) treatment, MAVYRET®/MAVIRET®. The material decline in its main revenue stream negatively impacted investor confidence during the specified period.
2. Widened Net Loss Due to Increased Royalty-Related Interest Expense.
The company reported a wider net loss of $19.5 million for fiscal Q3 2026, compared to a net loss of $18.3 million in the corresponding fiscal Q3 2025. This increase in net loss was largely attributable to higher royalty-related interest expenses, which more than offset reductions in operating costs, contributing to the stock's negative trend.
Show more
Enanta Pharmaceuticals (ENTA) stock has lost about 5% since 5/31/2026 because of the following key factors:
1. Significant Decline in Royalty Revenue.
Enanta Pharmaceuticals' total revenue for fiscal Q3 2026 (which ended June 30, 2026, as the company's fiscal year ends on September 30) sharply decreased by 21.6% year-over-year, to $14.4 million. This substantial reduction was primarily driven by lower royalty revenue from global net sales of AbbVie's hepatitis C virus (HCV) treatment, MAVYRET®/MAVIRET®. The material decline in its main revenue stream negatively impacted investor confidence during the specified period.
2. Widened Net Loss Due to Increased Royalty-Related Interest Expense.
The company reported a wider net loss of $19.5 million for fiscal Q3 2026, compared to a net loss of $18.3 million in the corresponding fiscal Q3 2025. This increase in net loss was largely attributable to higher royalty-related interest expenses, which more than offset reductions in operating costs, contributing to the stock's negative trend.
3. Ongoing Patent Litigation Uncertainty.
Enanta Pharmaceuticals continues to face uncertainty regarding its patent portfolio, a critical asset for its royalty income. The company filed for a rehearing after the Federal Circuit invalidated claims in its U.S. patent. Additionally, a separate European Unified Patent Court hearing is scheduled for later in fiscal Q4 2026, specifically on September 29, 2026. This unresolved legal situation introduces risk concerning the long-term stability of royalty revenue from MAVYRET®/MAVIRET®, which remains a significant financial consideration.
Show less
Stock Movement Drivers
Fundamental Drivers
The -7.3% change in ENTA stock from 5/31/2026 to 9/18/2026 was primarily driven by a -5.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312026 | 9182026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.16 | 12.20 | -7.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 69 | 65 | -5.7% |
| P/S Multiple | 5.5 | 5.4 | -1.5% |
| Shares Outstanding (Mil) | 29 | 29 | -0.2% |
| Cumulative Contribution | -7.3% |
Market Drivers
5/31/2026 to 9/18/2026| Return | Correlation | |
|---|---|---|
| ENTA | -7.3% | |
| Market (SPY) | 0.9% | 2.8% |
| Sector (XLV) | 12.7% | 30.1% |
Fundamental Drivers
The -14.7% change in ENTA stock from 2/28/2026 to 9/18/2026 was primarily driven by a -11.4% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9182026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.30 | 12.20 | -14.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 67 | 65 | -2.6% |
| P/S Multiple | 6.1 | 5.4 | -11.4% |
| Shares Outstanding (Mil) | 29 | 29 | -1.2% |
| Cumulative Contribution | -14.7% |
Market Drivers
2/28/2026 to 9/18/2026| Return | Correlation | |
|---|---|---|
| ENTA | -14.7% | |
| Market (SPY) | 11.6% | 22.6% |
| Sector (XLV) | 5.5% | 33.3% |
Fundamental Drivers
The 45.2% change in ENTA stock from 8/31/2025 to 9/18/2026 was primarily driven by a 96.3% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9182026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.40 | 12.20 | 45.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 65 | 65 | 0.7% |
| P/S Multiple | 2.8 | 5.4 | 96.3% |
| Shares Outstanding (Mil) | 21 | 29 | -26.5% |
| Cumulative Contribution | 45.2% |
Market Drivers
8/31/2025 to 9/18/2026| Return | Correlation | |
|---|---|---|
| ENTA | 45.2% | |
| Market (SPY) | 19.4% | 11.9% |
| Sector (XLV) | 24.1% | 8.8% |
Fundamental Drivers
The -17.8% change in ENTA stock from 8/31/2023 to 9/18/2026 was primarily driven by a -27.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312023 | 9182026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.85 | 12.20 | -17.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 81 | 65 | -19.0% |
| P/S Multiple | 3.9 | 5.4 | 40.2% |
| Shares Outstanding (Mil) | 21 | 29 | -27.6% |
| Cumulative Contribution | -17.8% |
Market Drivers
8/31/2023 to 9/18/2026| Return | Correlation | |
|---|---|---|
| ENTA | -17.8% | |
| Market (SPY) | 75.6% | 18.0% |
| Sector (XLV) | 32.3% | 20.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ENTA Return | 78% | -38% | -80% | -39% | 174% | -21% | -70% |
| Peers Return | 7% | -14% | -9% | -9% | 89% | 15% | 64% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| ENTA Win Rate | 50% | 50% | 25% | 50% | 67% | 44% | |
| Peers Win Rate | 45% | 43% | 42% | 42% | 65% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| ENTA Max Drawdown | -29% | -50% | -85% | -67% | -50% | -30% | |
| Peers Max Drawdown | -43% | -43% | -40% | -39% | -37% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GILD, VIR, ARWR, ABUS, IONS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
| Event | ENTA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -48.7% | -18.8% |
| % Gain to Breakeven | 94.8% | 23.1% |
| Time to Breakeven | 131 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.8% | -7.8% |
| % Gain to Breakeven | 26.2% | 8.5% |
| Time to Breakeven | 411 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -24.6% | -33.7% |
| % Gain to Breakeven | 32.6% | 50.9% |
| Time to Breakeven | 27 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -20.4% | -19.2% |
| % Gain to Breakeven | 25.7% | 23.8% |
| Time to Breakeven | 32 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -15.6% | -3.7% |
| % Gain to Breakeven | 18.5% | 3.9% |
| Time to Breakeven | 8 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -47.9% | -12.2% |
| % Gain to Breakeven | 91.9% | 13.9% |
| Time to Breakeven | 564 days | 62 days |
In The Past
Enanta Pharmaceuticals's stock fell -48.7% during the 2025 US Tariff Shock. Such a loss loss requires a 94.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ENTA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -48.7% | -18.8% |
| % Gain to Breakeven | 94.8% | 23.1% |
| Time to Breakeven | 131 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.8% | -7.8% |
| % Gain to Breakeven | 26.2% | 8.5% |
| Time to Breakeven | 411 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -24.6% | -33.7% |
| % Gain to Breakeven | 32.6% | 50.9% |
| Time to Breakeven | 27 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -20.4% | -19.2% |
| % Gain to Breakeven | 25.7% | 23.8% |
| Time to Breakeven | 32 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -47.9% | -12.2% |
| % Gain to Breakeven | 91.9% | 13.9% |
| Time to Breakeven | 564 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -48.7% | -6.8% |
| % Gain to Breakeven | 95.0% | 7.3% |
| Time to Breakeven | 564 days | 15 days |
In The Past
Enanta Pharmaceuticals's stock fell -48.7% during the 2025 US Tariff Shock. Such a loss loss requires a 94.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology company dedicated to the discovery and development of small molecule drugs. The company focuses its efforts on creating novel therapeutic solutions for the treatment of challenging viral infections and various liver diseases. Through its research, Enanta aims to address significant unmet medical needs in these areas.
The core of Enanta's business involves a robust research and development pipeline targeting several critical pathogens. This includes programs for respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus, and hepatitis B virus. Additionally, Enanta has a significant history of successful collaborations, notably with Abbott Laboratories (now AbbVie). This partnership led to the development of key compounds like paritaprevir and glecaprevir, which are utilized in combination therapies for chronic hepatitis C virus infections.
Enanta's primary market consists of patients affected by these severe viral and liver diseases, and the healthcare systems that treat them. The company's business model involves both advancing its own drug candidates and partnering with larger pharmaceutical companies to develop and commercialize these treatments, ultimately bringing innovative medicines to patients globally.
AI Analysis | Feedback
Here are 1-3 brief analogies for Enanta Pharmaceuticals (ENTA):
A focused biotech like a smaller Gilead Sciences, specializing in discovering new small molecule drugs for viral infections and liver diseases.
An "idea factory" for innovative antiviral and liver disease treatments, similar to how a smaller biotech develops promising drug candidates and then partners with a larger pharmaceutical company (like their past success with Abbott/AbbVie for Hepatitis C) for commercialization.
AI Analysis | Feedback
Major Products of Enanta Pharmaceuticals:
- Paritaprevir: A protease inhibitor compound developed and commercialized for the treatment of chronic hepatitis C virus.
- Glecaprevir: A protease inhibitor compound developed and commercialized for the treatment of chronic hepatitis C virus.
AI Analysis | Feedback
Enanta Pharmaceuticals (ENTA) is a biotechnology company that primarily sells its intellectual property and drug candidates to other companies through collaborative development and license agreements. It does not sell directly to individuals.
Based on the provided information, Enanta Pharmaceuticals' major customer and partner is:
- Abbott Laboratories (NYSE: ABT) - Enanta has a collaborative development and license agreement with Abbott Laboratories for HCV NS3 and NS3/4A protease inhibitor compounds.
AI Analysis | Feedback
AI Analysis | Feedback
Jay R. Luly, Ph.D. President, Chief Executive Officer and Director
Dr. Luly has been leading Enanta Pharmaceuticals since July 2003, navigating its growth through venture-financed years, a successful IPO in 2013, and major collaborations that have delivered over $1 billion in non-dilutive financing. Under his leadership, Enanta collaborated with AbbVie in the discovery and development of two hepatitis C virus protease inhibitors, glecaprevir and paritaprevir, which are components of the commercialized MAVYRET® and VIEKIRA PAK® regimens. Before joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. He previously held positions as Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals, following its acquisition of LeukoSite, Inc. in 1999. Prior to that, he was Senior Vice President, Drug Discovery and Preclinical Development at Leukosite and held several senior drug discovery positions at Abbott Laboratories from 1983 to 1997.
Harry R. Trout, III Interim Principal Financial Officer
Mr. Trout was appointed as the interim principal financial officer for Enanta Pharmaceuticals on August 26, 2025. He has been with Enanta since 2002 and has served as the Vice President of Finance since 2020.
Tara L. Kieffer, Ph.D. Chief Product Strategy Officer
Dr. Kieffer joined Enanta Pharmaceuticals in December 2020. Prior to Enanta, she gained extensive experience at Vertex Pharmaceuticals, where her roles included Vice President, External Innovation, Business Development, and Vice President, Integrated Program Management. She also served as Senior Director, Chief of Staff to the Chief Medical Officer, Director, Clinical Biomarkers, and Head of Clinical Virology at Vertex. Before her tenure at Vertex, Dr. Kieffer conducted research at Johns Hopkins University School of Medicine in the Department of Molecular Biology and Genetics.
Matthew P. Kowalsky, J.D. Chief Legal Officer
Mr. Kowalsky joined Enanta Pharmaceuticals in April 2024, bringing over 20 years of legal experience in the life sciences industry. Before Enanta, he held increasingly responsible legal and operational roles at Sigilon Therapeutics, Inc., serving as Chief of Staff and Chief Legal and Administrative Officer. Sigilon Therapeutics was acquired by Eli Lilly in 2023. Prior to Sigilon, Mr. Kowalsky was Vice President of Legal and Corporate Secretary at Proteon Therapeutics, Inc. from 2016 to 2019. His earlier career included positions as Senior Corporate Counsel at Sanofi Genzyme and similar legal roles at Cubist Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc., and Lantheus Medical Imaging, Inc. (formerly Bristol-Myers Squibb Medical Imaging, Inc.). He began his legal career at Choate, Hall & Stewart LLP and served as a surface warfare officer in the U.S. Navy before attending law school.
Brendan Luu Chief Business Officer
Mr. Luu joined Enanta Pharmaceuticals in January 2021. He previously spent 17 years at Merck KGaA, where he held various positions of increasing responsibility, most recently as Vice President and Global Head of Oncology Business Development. In this role, he was responsible for developing and executing the franchise business development strategy, including significant transactions across all stages of drug development. He also served as Senior Director and Global Head of Business Development, Strategic Initiatives, and Director, Global Licensing and Business Development, Neurology and Immunology. Earlier in his career, Mr. Luu held roles in the chemicals industry with BASF Corporation and in telecommunications with Tyco International.
AI Analysis | Feedback
Key Risks to Enanta Pharmaceuticals (ENTA)
- High-Risk, Concentrated Pipeline and Clinical Development Failures: Enanta Pharmaceuticals' future revenue and growth are heavily dependent on the successful discovery, development, and commercialization of a limited number of drug candidates within its virology and immunology pipelines. Drug development is inherently risky, characterized by a high rate of failure in clinical trials. The company's lead Respiratory Syncytial Virus (RSV) program, zelicapavir, has experienced past setbacks, although it has recently shown positive data in high-risk populations. Enanta's strategic pivot into immunology also introduces risks due to the highly competitive nature of the field and the need to establish credibility in a new therapeutic area.
- Declining Royalty Revenue: Enanta Pharmaceuticals currently derives a significant portion of its revenue from royalties generated through a collaboration with AbbVie for Hepatitis C Virus (HCV) products. However, this royalty income is declining and is projected to be fully eroded by patent expirations, with the earliest key patent expiring around June 2030. This impending loss of a stable revenue source increases the company's reliance on its pipeline for future commercial success and profitability.
- Intense Competition and Partnering Delays: Enanta operates in highly competitive pharmaceutical markets for both its virology (including RSV) and immunology programs. The company faces competition from other pharmaceutical firms developing vaccines and treatments for RSV. Delays in securing partnerships for its RSV programs are critical for their advancement into later-stage trials and could allow competitors to gain a market advantage. Without sufficient partner resources and expertise, Enanta may face challenges in funding and executing the extensive clinical trials required for regulatory approval.
AI Analysis | Feedback
The recent approval and rollout of preventative measures for Respiratory Syncytial Virus (RSV), including vaccines (such as Arexvy from GSK and Abrysvo from Pfizer) for older adults and pregnant individuals, and monoclonal antibodies (such as Beyfortus from AstraZeneca/Sanofi) for infants and young children. These preventative therapies aim to significantly reduce the incidence, hospitalization, and severity of RSV infections across different age groups. This emerging landscape of highly effective preventative options poses a clear threat to the commercial potential and market demand for therapeutic antiviral drugs for RSV, such as those Enanta Pharmaceuticals is developing.
AI Analysis | Feedback
Enanta Pharmaceuticals (ENTA) targets several significant addressable markets with its product and service pipeline:
-
Respiratory Syncytial Virus (RSV) Treatments: The global respiratory syncytial virus therapeutics market was valued at approximately USD 5.8 billion in 2023 and is projected to reach USD 16.7 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.8% from 2024 to 2032. North America held a significant share of this market, accounting for USD 2.5 billion in 2023.
-
SARS-CoV-2 (COVID-19) Treatments: The global COVID-19 therapeutics market size was estimated at USD 32.54 billion in 2025. However, this market is projected to decrease to USD 8.70 billion by 2033, with a CAGR of -15.20% from 2025 to 2033. Another report indicates the global COVID-19 therapeutics market size is projected to exceed US$ 16.2 billion by the end of 2031. North America held a substantial portion of the global market, with a market size of USD 13.02 billion in 2025.
-
Human Metapneumovirus (hMPV) Treatments: The global Human Metapneumovirus (hMPV) therapeutics market is estimated to be valued at USD 494.1 million in 2025 and is expected to reach USD 767.7 million by 2032, growing at a CAGR of 6.5% from 2025 to 2032. North America is projected to lead this market, holding an estimated 39.3% share in 2025.
-
Hepatitis B Virus (HBV) Treatments: The global hepatitis B therapeutics market was valued at approximately USD 2.96 billion in 2025 and is projected to reach around USD 7.77 billion by 2032, growing at a strong CAGR of 14.78%. The chronic Hepatitis B market in the 7MM (United States, EU4, United Kingdom, and Japan) was valued at approximately USD 1.603 billion in 2025. North America is a dominant region in the HBV therapeutics market, with a market share of 52.31% in 2025.
-
Hepatitis C Virus (HCV) Treatments: The global hepatitis C drugs market size was valued at USD 13.03 billion in 2024 and is projected to grow to USD 18.86 billion by 2033, at a CAGR of 4.2%. Another projection indicates the global hepatitis C drugs market will grow from USD 19.51 billion in 2024 to USD 26.14 billion in 2032. North America is the largest regional market for Hepatitis C, holding an estimated 34.7% share. The North American hepatitis treatment market is expected to reach USD 13.4 billion by 2032.
AI Analysis | Feedback
Enanta Pharmaceuticals (NASDAQ: ENTA) is anticipated to drive future revenue growth over the next 2-3 years primarily through the advancement and potential commercialization of its pipeline assets, particularly in the areas of Respiratory Syncytial Virus (RSV) and immunology. The company's current revenue primarily stems from royalties on AbbVie's global MAVYRET/MAVIRET net product sales, which have been experiencing a decline.
The key expected drivers of future revenue growth for Enanta Pharmaceuticals include:
-
Advancement and Potential Commercialization of Zelicapavir for RSV: Enanta's lead RSV candidate, zelicapavir (an N-protein inhibitor), is a significant potential revenue driver. The company is actively conducting Phase 3 enabling activities and engaging with the FDA to advance this program. Positive Phase 2 data have indicated clinically meaningful benefits in reducing symptom duration and hospitalization rates in high-risk adults. Progression to a Phase 3 trial and subsequent potential market launch, potentially with a partner, could unlock a new and substantial revenue stream for Enanta.
-
Development of EDP-323 as a Next-Generation RSV Treatment: Another promising RSV candidate, EDP-323 (an L-protein polymerase inhibitor), has demonstrated rapid viral load reductions in human challenge studies. While zelicapavir is further along, EDP-323 is being evaluated for its potential in combination strategies or for post-exposure prophylaxis, offering an additional avenue for revenue growth within the RSV market if successfully developed and commercialized.
-
Expansion and Progression of the Oral Immunology Pipeline: Enanta is strategically building an immunology portfolio focused on developing small molecule inhibitors for type 2 immune-driven diseases. This pipeline includes several programs with upcoming milestones that could contribute to future revenue:
- EDP-978 (KIT inhibitor): This clinical candidate for chronic spontaneous urticaria and other mast cell-driven diseases is on track for an Investigational New Drug (IND) application filing in the first quarter of 2026, with Phase 1 data expected in the fourth quarter of 2026.
- EPS-3903 (STAT6 inhibitor): This oral, once-daily development candidate, targeting the IL-4/IL-13 pathway for inflammatory diseases, is anticipated to have an IND filing in the second half of 2026.
- MRGPRX2 Inhibition Program: Enanta introduced a new discovery program focusing on MRGPRX2 inhibition for chronic inflammatory diseases, with a development candidate selection expected in the second half of 2026.
AI Analysis | Feedback
Share Issuance
- Enanta Pharmaceuticals issued common stock valued at $21.26 million in fiscal year 2022.
- The company issued common stock worth $3.61 million in fiscal year 2021.
- In fiscal year 2023, share issuances amounted to $2.21 million.
Inbound Investments
- In April 2023, Enanta Pharmaceuticals received an upfront payment of $200 million from OMERS, a Canadian pension plan, for selling 54.5% of its ongoing MAVYRET®/MAVIRET® royalties from AbbVie. This transaction was structured such that the upfront payment was recorded as a liability, with a portion of future royalty payments directed to OMERS until a cap of 1.42 times the purchase payment is met, after which full royalties revert to Enanta.
Capital Expenditures
- Capital expenditures were $17.95 million in fiscal year 2024.
- The company reported capital expenditures of $12.90 million in fiscal year 2025.
- In fiscal year 2023, capital expenditures totaled $9.06 million. These expenditures generally focus on funding long-term assets and infrastructure, supporting the company's research and development activities.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 15.4% | 45.5% | 86.6% | CAH 378% · MCK 331% · COR 164% |
| Managed Health Care | 8 | 39.0% | -2.8% | 0.1% | OSCR 84% · HQY 49% · ELV 16% |
| Health Care Services | 20 | 20.1% | 39.2% | -1.3% | HIMS 221% · RDNT 166% · DGX 75% |
| Health Care Facilities | 24 | 4.2% | 3.1% | -13.4% | NHC 269% · THC 259% · ENSG 125% |
| Health Care Equipment | 50 | -3.2% | -5.0% | -22.6% | POCI 11050% · UFPT 336% · GKOS 204% |
| Pharmaceuticals | 62 | -8.2% | 11.7% | -40.1% | LQDA 2386% · INDV 1146% · ETON 982% |
| Health Care Supplies | 12 | 13.1% | -12.7% | -40.8% | LNTH 293% · HAE 54% · MMSI 19% |
| Life Sciences Tools & Services | 109 | 5.2% | -17.4% | -68.8% | SNWV 1757% · MEDP 229% · NTRA 192% |
| Biotechnology ← | 364 | -0.7% | -25.7% | -79.5% | CELZ 1280% · DNTH 1143% · ELVN 1058% |
| Health Care Technology | 21 | -23.7% | -51.7% | -79.9% | SPOK 72% · HSTM 2% · VEEV -14% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Enanta Pharmaceuticals Earnings Notes | 12/16/2025 | |
| Can Enanta Pharmaceuticals Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 28.32 |
| Mkt Cap | 4.6 |
| Rev LTM | 486 |
| Op Inc LTM | -143 |
| FCF LTM | -56 |
| FCF 3Y Avg | -134 |
| CFO LTM | -47 |
| CFO 3Y Avg | -91 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.2% |
| Rev Chg 3Y Avg | 185.4% |
| Rev Chg Q | -5.7% |
| QoQ Delta Rev Chg LTM | -1.3% |
| Op Inc Chg LTM | 23.5% |
| Op Inc Chg 3Y Avg | -5.6% |
| Op Mgn LTM | -50.9% |
| Op Mgn 3Y Avg | -235.2% |
| QoQ Delta Op Mgn LTM | -0.7% |
| CFO/Rev LTM | -33.8% |
| CFO/Rev 3Y Avg | -223.9% |
| FCF/Rev LTM | -35.1% |
| FCF/Rev 3Y Avg | -232.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Discovering and developing small molecule drugs with an emphasis on virology and immunology | 65 | 68 | 79 | 86 | |
| License revenue | 0 | ||||
| Royalty revenue | 97 | ||||
| Total | 65 | 68 | 79 | 86 | 97 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Discovering and developing small molecule drugs with an emphasis on virology and immunology | -85 | -122 | -137 |
| Total | -85 | -122 | -137 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Discovering and developing small molecule drugs with an emphasis on virology and immunology | -82 | -116 | -134 |
| Total | -82 | -116 | -134 |
Price Behavior
| Market Price | $12.20 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 03/21/2013 | |
| Distance from 52W High | -27.6% | |
| 50 Days | 200 Days | |
| DMA Price | $13.27 | $13.56 |
| DMA Trend | up | up |
| Distance from DMA | -8.1% | -10.1% |
| 3M | 1YR | |
| Volatility | 42.6% | 107.2% |
| Downside Capture | 47.31 | 96.07 |
| Upside Capture | 22.59 | 130.90 |
| Correlation (SPY) | 9.9% | 12.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.35 | 0.58 | -0.07 | 0.74 | 0.94 | 0.98 |
| Up Beta | 1.36 | 2.03 | 1.32 | 1.25 | 0.96 | 0.60 |
| Down Beta | 0.53 | -0.47 | -0.32 | 0.31 | 0.44 | 1.13 |
| Up Capture | 162% | -15% | -35% | 48% | 122% | 83% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 10 | 16 | 29 | 65 | 127 | 358 |
| Down Capture | 120% | 82% | -59% | 91% | 82% | 105% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 11 | 26 | 35 | 61 | 120 | 384 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENTA | |
|---|---|---|---|---|
| ENTA | 62.1% | 107.1% | 0.80 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | 7.2% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 12.4% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | 9.5% |
| Commodities (DBC) | 46.9% | 20.6% | 1.76 | -10.1% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | 7.8% |
| Bitcoin (BTCUSD) | -34.5% | 43.9% | -0.84 | 15.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENTA | |
|---|---|---|---|---|
| ENTA | -25.7% | 73.6% | -0.13 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | 23.4% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 22.7% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 7.9% |
| Commodities (DBC) | 11.3% | 19.5% | 0.45 | 0.3% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 22.3% |
| Bitcoin (BTCUSD) | 11.2% | 52.5% | 0.39 | 14.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENTA | |
|---|---|---|---|---|
| ENTA | -5.9% | 60.8% | 0.13 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 29.1% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 28.9% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 5.9% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 6.9% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | 24.5% |
| Bitcoin (BTCUSD) | 61.7% | 66.1% | 1.02 | 9.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/11/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/10/2026 | -2.1% | -7.1% | -4.1% |
| 5/11/2026 | -6.0% | -13.0% | -24.3% |
| 2/9/2026 | 2.2% | 0.2% | 2.5% |
| 11/17/2025 | -3.6% | 6.5% | 13.3% |
| 8/11/2025 | 5.7% | 25.9% | 28.4% |
| 5/12/2025 | -5.8% | 7.4% | 43.2% |
| 2/10/2025 | 14.1% | 52.9% | 48.4% |
| 11/25/2024 | -5.0% | -2.8% | -33.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 10 |
| # Negative | 15 | 15 | 14 |
| Median Positive | 5.9% | 7.7% | 19.0% |
| Median Negative | -4.2% | -7.9% | -12.8% |
| Max Positive | 15.1% | 52.9% | 48.4% |
| Max Negative | -25.7% | -24.6% | -37.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/10/2026 | -2.1% | -7.1% | -4.1% |
| 5/11/2026 | -6.0% | -13.0% | -24.3% |
| 2/9/2026 | 2.2% | 0.2% | 2.5% |
| 11/17/2025 | -3.6% | 6.5% | 13.3% |
| 8/11/2025 | 5.7% | 25.9% | 28.4% |
| 5/12/2025 | -5.8% | 7.4% | 43.2% |
| 2/10/2025 | 14.1% | 52.9% | 48.4% |
| 11/25/2024 | -5.0% | -2.8% | -33.4% |
| 8/5/2024 | 1.2% | -4.0% | -5.5% |
| 5/6/2024 | -10.3% | -11.6% | -15.1% |
| 2/7/2024 | 0.8% | 7.7% | 25.6% |
| 11/20/2023 | 11.5% | 8.6% | -4.7% |
| 8/7/2023 | -4.2% | -18.5% | -37.3% |
| 5/8/2023 | -25.7% | -24.6% | -23.4% |
| 2/7/2023 | -3.5% | -8.8% | -14.7% |
| 11/21/2022 | -2.1% | -9.6% | 1.2% |
| 8/8/2022 | -4.2% | -1.1% | -10.8% |
| 5/9/2022 | 6.5% | -7.9% | -17.9% |
| 2/8/2022 | 5.9% | 1.7% | 7.0% |
| 11/22/2021 | 15.1% | 17.4% | 2.9% |
| 8/5/2021 | -3.0% | -0.2% | 24.8% |
| 5/6/2021 | -4.9% | -1.4% | -4.0% |
| 2/8/2021 | -0.4% | -8.6% | -7.2% |
| 11/23/2020 | -1.8% | -5.7% | -3.1% |
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 10 |
| # Negative | 15 | 15 | 14 |
| Median Positive | 5.9% | 7.7% | 19.0% |
| Median Negative | -4.2% | -7.9% | -12.8% |
| Max Positive | 15.1% | 52.9% | 48.4% |
| Max Negative | -25.7% | -24.6% | -37.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/12/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 02/11/2026 | 10-Q |
| 09/30/2025 | 11/19/2025 | 10-K |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-Q |
| 09/30/2024 | 11/27/2024 | 10-K |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/22/2023 | 10-K |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/08/2023 | 10-Q |
| 09/30/2022 | 11/23/2022 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/12/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 02/11/2026 | 10-Q |
| 09/30/2025 | 11/19/2025 | 10-K |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-Q |
| 09/30/2024 | 11/27/2024 | 10-K |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/22/2023 | 10-K |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/08/2023 | 10-Q |
| 09/30/2022 | 11/23/2022 | 10-K |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/10/2022 | 10-Q |
| 09/30/2021 | 11/24/2021 | 10-K |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 02/09/2021 | 10-Q |
| 09/30/2020 | 11/25/2020 | 10-K |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 02/10/2020 | 10-Q |
| 09/30/2019 | 11/27/2019 | 10-K |
Insider Activity
Updated 8/10/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Capps, Kathleen S | See Remarks | Direct | Sell | 12052025 | 14.23 | 323 | 4,596 | 119,205 | Form |
| 2 | Trout, Harry R Iii | See Remarks | Direct | Sell | 12052025 | 14.23 | 542 | 7,713 | 232,632 | Form |
| 3 | Rottinghaus, Scott T | Chief Medical Officer | Direct | Sell | 12052025 | 14.23 | 798 | 11,356 | 310,100 | Form |
| 4 | Luu, Brendan | Chief Business Officer | Direct | Sell | 12052025 | 14.23 | 1,394 | 19,837 | 545,422 | Form |
| 5 | Kieffer, Tara Lynn | Chief Product Strategy Officer | Direct | Sell | 12052025 | 14.23 | 2,106 | 29,968 | 435,723 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Capps, Kathleen S | See Remarks | Direct | Sell | 12052025 | 14.23 | 323 | 4,596 | 119,205 | Form |
| 2 | Trout, Harry R Iii | See Remarks | Direct | Sell | 12052025 | 14.23 | 542 | 7,713 | 232,632 | Form |
| 3 | Rottinghaus, Scott T | Chief Medical Officer | Direct | Sell | 12052025 | 14.23 | 798 | 11,356 | 310,100 | Form |
| 4 | Luu, Brendan | Chief Business Officer | Direct | Sell | 12052025 | 14.23 | 1,394 | 19,837 | 545,422 | Form |
| 5 | Kieffer, Tara Lynn | Chief Product Strategy Officer | Direct | Sell | 12052025 | 14.23 | 2,106 | 29,968 | 435,723 | Form |
| 6 | Or, Yat Sun | Chief Scientific Officer | Direct | Sell | 12052025 | 14.23 | 2,390 | 34,010 | 5,284,908 | Form |
| 7 | Luly, Jay R | President and CEO | Direct | Sell | 12052025 | 14.23 | 4,743 | 67,493 | 12,209,710 | Form |
| 8 | Capps, Kathleen S | See Remarks | Direct | Sell | 12032025 | 13.96 | 207 | 2,890 | 121,452 | Form |
| 9 | Trout, Harry R Iii | See Remarks | Direct | Sell | 12032025 | 13.96 | 380 | 5,305 | 235,784 | Form |
Investor Activity (13F)
Updated Sep 19, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.